427 related articles for article (PubMed ID: 8796140)
1. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
3. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.
Stuenkel CA; Dudley RE; Yen SS
J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483
[TBL] [Abstract][Full Text] [Related]
4. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of testosterone pellets in man.
Handelsman DJ; Conway AJ; Boylan LM
J Clin Endocrinol Metab; 1990 Jul; 71(1):216-22. PubMed ID: 2115044
[TBL] [Abstract][Full Text] [Related]
6. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
[TBL] [Abstract][Full Text] [Related]
7. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
8. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
Winters SJ; Atkinson L
Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
[TBL] [Abstract][Full Text] [Related]
9. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial of testosterone replacement therapy in hypogonadal men.
Conway AJ; Boylan LM; Howe C; Ross G; Handelsman DJ
Int J Androl; 1988 Aug; 11(4):247-64. PubMed ID: 3139571
[TBL] [Abstract][Full Text] [Related]
11. An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101.
Wittert GA; Harrison RW; Buckley MJ; Wlodarczyk J
Andrology; 2016 Jan; 4(1):41-5. PubMed ID: 26754331
[TBL] [Abstract][Full Text] [Related]
12. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion.
Mechlin CW; Frankel J; McCullough A
J Sex Med; 2014 Jan; 11(1):254-61. PubMed ID: 24119010
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.
McMahon CG; Shusterman N; Cohen B
J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432
[TBL] [Abstract][Full Text] [Related]
16. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
[TBL] [Abstract][Full Text] [Related]
17. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA
J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
20. Which testosterone replacement therapy?
Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
